Program
xelox
Also written as “XELOX”, “IDX-1197+XELOX” and “SSGJ-706+Bevacizumab+XELOX”.
Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 7 companies.
Drug pageXelox: every studyMany companies study it; this page follows only the 8 they lead. All 60 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 21 open or running | phase 3since Nov 13, 2006 | Nov 13, 2006 | Nov 30, 2027phase 2 · NCT05702229 |
| 3SBioits history only | 11 open or running | phase 2since Nov 14, 2025 | Nov 14, 2025 | Dec 2026phase 2 · NCT07233850 |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Oct 11, 2006 | Oct 11, 2006 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since Sep 29, 2024 | Sep 29, 2024 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 3since Jul 6, 2006 | Jul 6, 2006 | none ahead |
| Idienceits history only | 11 open or running | phase 2since Jan 13, 2021 | Jan 13, 2021 | none ahead |
| Sichuan Luzhou Buchang Biopharmaceuticalits history only | 11 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2006First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT00399035 · 1,254 enrolled · Argentina, Australia, Brazil and more
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsNCT05702229 · 163 planned · United States, China, Japan and more
Ahead
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | Nov 30, 2027 | 163 |
| NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more | 3 | Completed | Mar 2010 | 1,254 |
How it is read
Names in the registry
- “XELOX”, 2 entries
- “IDX-1197+XELOX”, 1 entry
- “SSGJ-706+Bevacizumab+XELOX”, 1 entry
- “HS-20117+CAPEOX”, 1 entry
- “BC001+Sintilimab+XELOX”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 4 studies
- Stomach Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.